Turnaround in Place at Cochlear

Hearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.
Read MoreHearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.
Read MoreCOVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read MoreNoxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. The company’s CEO Dr Graham Kelly tells us more.
Read MoreAlex Cook from BetaShares examines the role robotics and A.I. have played not only in developing a vaccine but also in its distribution.
Read MoreGrowth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge.
Read MoreCorporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.
Read MoreIn this video, immunotherapy pioneer Immutep’s (ASX: IMM) CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments.
Read MoreMark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.
Read MoreWith the COVID-19 pandemic dominating markets, politics, and everyday life, it’s no wonder that Warren Buffett has moved heavily into pharma and medical stocks in the quarterly latest fund manager filing with the US Securities and Exchange Commission.
Read MorePfizer and BioNTech have announced preliminary data from a late-stage clinical trial for their COVID-19 vaccine candidate, and the results were better than expected. Matt Peron and Andy Acker from Janus Henderson Investors explain what this means for the fight to end the pandemic and the next leg of the market cycle.
Read MoreWith Alphinity celebrating its 10th anniversary we have explored what has happened in the healthcare sector in the decade since Alphinity was first established.
Read MoreTwo announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.
Read MoreAs an analyst who follows biopharma companies, I take an interest in the US Food and Drug Administration (FDA), while as an American/Australian, US politics, particularly, in the days of Trump, is also an interest. Then, there is an ASX-listed cellular therapy company called Mesoblast (ASX:MSB), which I have followed pretty much since it listed in 2004.
Read MoreDrugs and biologics often end up with multiple names as they travel through the development and commercialisation. It can all get very confusing and even more so after the therapeutic is on the market but turns out to have multiple different names across multiple different jurisdictions.
Read More